BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16227426)

  • 1. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
    Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
    Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.
    Voulgari PV; Venetsanopoulou AI; Epagelis EK; Alamanos Y; Takalou I; Drosos AA
    Ann Rheum Dis; 2007 Feb; 66(2):270-1. PubMed ID: 17068063
    [No Abstract]   [Full Text] [Related]  

  • 4. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
    Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
    Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Infliximab].
    Herrera E; Habicheyn S
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
    Bartke U; Venten I; Kreuter A; Gubbay S; Altmeyer P; Brockmeyer NH
    Br J Dermatol; 2004 Apr; 150(4):784-6. PubMed ID: 15099388
    [No Abstract]   [Full Text] [Related]  

  • 9. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
    Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
    Cisternas M; GutiƩrrez M; Jacobelli S
    Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
    [No Abstract]   [Full Text] [Related]  

  • 11. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
    Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
    Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
    [No Abstract]   [Full Text] [Related]  

  • 12. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG; Mody E; Husni ME; Qureshi AA
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of infliximab for the treatment of psoriatic arthritis.
    Ritchlin C
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):300-1. PubMed ID: 16932707
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis.
    Lehnen M; Franckson T; Knab J; Hoeft D; Grabbe S; Dissemond J
    Br J Dermatol; 2005 Jul; 153(1):212-4. PubMed ID: 16029357
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteomyelitis occurring during infliximab treatment of severe psoriasis.
    Sri JC; Tsai CL; Deng A; Gaspari AA
    J Drugs Dermatol; 2007 Feb; 6(2):207-10. PubMed ID: 17373180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriatic arthritis patients doing better on infliximab than etanercept.
    Smith N; Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
    [No Abstract]   [Full Text] [Related]  

  • 18. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
    Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
    Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment of psoriatic arthritis with infliximab.
    Yazdani-Biuki B; Wohlfahrt K; Mulabecirovic A; Mueller T; Hermann J; Graninger WB; Brezinschek HP; Brezinschek RI
    Ann Rheum Dis; 2004 Nov; 63(11):1531-2; author reply 1532. PubMed ID: 15479917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.